ArticleAmerican journal of clinical dermatology2021
The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses.
Article in American journal of clinical dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Complementary and Alternative Therapies for Onychomycosis: A Systematic Review of the Clinical Evidence.Skin appendage disorders · 2022Pooled it
- Trial
- Comparative study of safety and efficacy of combination therapy of fractional COLasers in medical science · 2023Trial
- Nail tattooing: a novel and minimally invasive technique for enhancing drug penetration through the nail.Drug delivery and translational research · 2026Article
- Biosynthesis of Silver Nanoparticles Using Endophytic Clonostachys rosea ZMS27 from Medicinal Plant Anemarrhena asphodeloides and its Antagonistic Activity Against Superficial Pathogenic Fungi.Molecular biotechnology · 2026Article
- Rapid Detection of Fungi in Nail Specimens Using Multi-Tube Recombinase Polymerase Amplification Assay.Mycoses · 2026Article
- Regulatory gaps in over-the-counter antifungal access for vulvovaginal candidiasis in Uganda: A policy analysis framework.IJID regions · 2025Article
- Formulation Studies on Microemulsion-Based Polymer Gels Loaded with Voriconazole for the Treatment of Skin Mycoses.Pharmaceutics · 2025Article
- An Assessment of the Antifungal Efficacy of a Novel Topical Onychomycosis Treatment Using Human Nail and Skin Infection Models.Journal of fungi (Basel, Switzerland) · 2025Article
- Synergistic activity between conventional antifungals and chalcone-derived compound against dermatophyte fungi and Candida spp.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Recognition of Antifungal-Resistant Dermatophytosis by Infectious Diseases Specialists, United States.Emerging infectious diseases · 2024Article
- Review
- Household Transmission of Tinea Infections: Analysis of a Large Commercial Health Insurance Claims Database, United States, 2021.Open forum infectious diseases · 2024Article
- Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance.American journal of clinical dermatology · 2024Review
- ------Topical Antifungal Prescribing for Medicare Part D Beneficiaries - United States, 2021.MMWR. Morbidity and mortality weekly report · 2024Article
- Prescribing of clotrimazole-betamethasone dipropionate, a topical combination corticosteroid-antifungal product, for Medicare part D beneficiaries, United States, 2016-2022.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial.Frontiers in medicine · 2024Article
- Majocchi's granuloma-A multicenter retrospective cohort study.JAAD international · 2023Article
- Concerning rates of laboratory-confirmed antifungal-resistant onychomycosis and tinea pedis: An online survey of podiatrists, United States.Health science reports · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superficial mycoses are becoming increasingly resistant to current antifungal medications. As alternative therapeutic options are limited, the increasing frequency of reports of antifungal resistance is alarming. This epidemic parallels the rise of antibiotic resistance; however, the significance of this problem has yet to gain global attention. Here, we discuss the reports of antifungal resistance from around the world, present our own experience with treatment-resistant infections, and examine alternative treatment strategies. The majority of reports of recalcitrant infections indicate terbinafine resistance as the causative factor. Single-point mutations in the squalene oxidase gene is the most reported mechanism of resistance to terbinafine. Mixed infections of dermatophytes with non-dermatophyte molds and/or yeasts are becoming more prevalent and contributing to the resistant nature of these infections. The key to selecting an effective antifungal therapy for a recalcitrant infection is identification of the infectious organisms(s) and testing susceptibility of the organism(s) to antifungal drugs. Combination and sequential therapy regimens are options, but both require active monitoring for hepatic and renal function, drug interactions, and other adverse effects. Selected topical antifungals with a wide spectrum of activity may also be considerations in some clinical presentations. Innovative treatment regimens and novel therapeutics are needed to overcome the rising epidemic of antifungal resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.